Year-End Report 25/26

Diamyd Medical reported a fiscal 2025/2026 net loss of MSEK 255.6, versus MSEK 169.8 a year earlier, while operating cash outflow increased to MSEK 195.3 from MSEK 169.7. Fourth-quarter net loss narrowed to MSEK 16.8 from MSEK 44.9; cash and short-term investments were MSEK 305.4 on August 31, 2026, up from MSEK 277.2. The Board proposed no dividend.

Analysis

The key signal is financing durability, not the reported loss itself: with negligible sales, the equity depends on clinical progress and continued access to capital. Trailing operating cash use implies roughly 19 months of cash at that rate, but this is only a rough runway estimate; the lower fourth-quarter outflow is encouraging only if it reflects a durable reduction rather than payment timing. Cash increased year over year despite operating outflows, so investors should verify financing proceeds and other cash movements before treating the balance as evidence of improving economics. Near term, the lower quarterly loss may temper concern, but it does not establish a path to self-funding. Over 1–3 months, trial updates, spending guidance, and any financing terms are the likely catalysts; over 6–18 months, continued clinical execution without material revenue leaves shareholders exposed to dilution if cash use persists. The contrarian point is that the annual deterioration may overstate the current burn trajectory, while the more important risk—cash runway and the timing/terms of the next funding event—cannot be resolved from this summary. No valuation, trial milestones, or financing details are provided, so a directional trade is not justified on these figures alone.

Key Decisions for Investors

• Treat DMYD.B as a financing- and catalyst-driven position, not an earnings-recovery story; avoid increasing exposure until the company provides a cash-flow bridge and updated trial timetable.
• Monitor cash and short-term investments against quarterly operating cash use, plus any financing proceeds, restricted cash, and committed trial costs. Reassess if the implied runway materially shortens or management signals a raise.
• For an existing position, size for potential dilution rather than assuming the current cash balance funds the next clinical milestones. Verify financing terms and the use of proceeds before interpreting a cash increase as positive.
• Falsifiers: sustained lower operating cash use alongside on-time clinical milestones would weaken the dilution-risk thesis; accelerating burn, delayed milestones, or a discounted equity raise would strengthen it. No options or pair trade is recommended without liquidity, valuation, and catalyst details.